Symbols

ENSC

Ensysce Biosciences·NASDAQ

--(--)

Signals Analysis

Bullish signal 0

Bearish signal 4

Significant Revenue Decline

EPS Below Expectations

Revenue Below Expectations

Consecutive Revenue Decline

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ENSC

Ensysce Biosciences, Inc.

A clinical stage pharmaceutical company seeking to develop innovative solutions for severe pain relief while reducing the fear of and the potential for misuse, abuse, and overdose

Industry

Pharmaceutical

Established Date

Listing Date

07/02/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.ensysce.com

Security Type

Common stock

Office address

7946 Ivanhoe Avenue Suite 201 La Jolla California 92037

Business

Introduction

Ensysce Biosciences, Inc., was incorporated in Delaware in April 2003. The company is a clinical-stage pharmaceutical company dedicated to developing innovative solutions to relieve severe pain while reducing the risk of opioid misuse, abuse and overdose. The company is currently developing product candidates designed to improve the safety of prescription drugs.

Company Financials

EPS

ENSC has released its 2025 Q4 earnings. EPS was reported at -0.75, versus the expected -1.08, beating expectations. The chart below visualizes how ENSC has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ENSC has released its 2025 Q4 earnings report, with revenue of 1.88M, reflecting a YoY change of 44.39%, and net profit of -2.77M, showing a YoY change of 22.34%. The Sankey diagram below clearly presents ENSC's revenue sources and cost distribution.